Johnson & Johnson’s Cordis Corp. is making strides when it comes to its own renal denervation system for treating high blood pressure—even as questions are raised overall about the treatment. Cordis announced Friday that it has won CE Mark approval for its Renlane system. Hannes Reuter, MD, at the University of Cologne Hospital in Germany, has made the first successful European uses of the Renlane Renal Denervation System, using it to treat patients with high blood pressure who had proved resistant to traditional drug therapies. The treatment involves applying radiofrequency ablation through a catheter to the renal arteries that supply the kidneys with blood, hopefully causing the kidneys to produce less of the hormones that cause chronic high blood pressure.
Help employers find you! Check out all the jobs and post your resume.
